Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
3281758 | Clinical Gastroenterology and Hepatology | 2014 | 9 Pages |
Abstract
A large number of patients worldwide receive anticoagulant and antiplatelet agents, collectively known as antithrombotic agents. Several new anticoagulants and antiplatelet agents recently were approved for use. Gastroenterologists may be unfamiliar with the mechanism of action, indications for use, and pharmacokinetics of these newer drugs. In patients undergoing elective and urgent endoscopic procedures, clinicians must be familiar with these medications to optimize outcomes. When the decision is made to continue the newer antithrombotic agents for elective procedures, the clinician must understand the risk that these agents may impart on procedural-induced bleeding. Finally, it is important to understand how to manage these agents in the presence of acute gastrointestinal bleeding. In this article the use of newer antithrombotic agents is reviewed.
Keywords
PCCFDAFEIBArFVIIaFVIICrClPCIDTIAPTTEndoscopic retrograde cholangiopancreatographyrecombinant FVIIaPulmonary embolismEndoscopyMyocardial infarctionDrug administration scheduleDVTDeep venous thrombosisprothrombin complex concentrateGastrointestinalactivated partial thromboplastin timethrombin timeprothrombin timeFood and Drug AdministrationFactor VIIAtrial fibrillationpercutaneous coronary interventiondirect thrombin inhibitorDrug monitoringERCP یا endoscopic retrograde cholangiopancreatography Creatinine clearance
Related Topics
Health Sciences
Medicine and Dentistry
Gastroenterology
Authors
Todd H. Baron, Patrick S. Kamath, Robert D. McBane,